Wave Life Sciences (WVE, $7.99) posts disappointing trial results from anti-Huntington disease drug
Biotech company Wave Life Sciences’ shares plummeted , after clinical test results on a anti-Huntington disease drug turned out to be a bit disappointing.
The trial, which compared the results from oligonucleotide therapeutic WVE-120102 with a placebo, showed a statistically significant 12.4% reduction in a disease-causing mutant huntingtin protein, at the highest doses tested ( as indicated in the Wave Life’s statement). However, “there was no difference" in total huntingtin protein compared with placebo, the company said.
The drug was generally safe and “well tolerated among patients receiving doses up to 16 mg in both single and multidose portions of the study,” according to Wave Life.
Wave Life conducted a Phase 1b/2a Precision-HD2 trial. Results from another Phase 1b/2a, Precision-HD1( evaluating WVE-120101 in early manifest Huntington patients) is expected to come out in the second half of next year, as indicated by the company.
Huntington disease often appears in adults in their 30s and 40s, is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability, according to the National Institutes of Health.
WVE's Stochastic Oscillator remains in overbought zone for 4 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WVE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for WVE entered a downward trend on June 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where WVE's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 01, 2026. You may want to consider a long position or call options on WVE as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for WVE just turned positive on June 09, 2026. Looking at past instances where WVE's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
WVE moved above its 50-day moving average on July 08, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WVE advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.237) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). WVE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (14.749) is also within normal values, averaging (434.181).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. WVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of nucleic acid therapeutics
Industry Biotechnology
Advertisement